14 More recently, a trial of aspirin in patients (mostly women) treated for breast cancer was stopped prematurely due to a strong trend to harm among those assigned to aspirin. 15 As with cardiovascular disease, it is important to consider all of the data.
← all excerpts
Commentary on Wittes et al: Aspirin for primary prevention of CV events - Rationally robust? Statistically significant? Clinically convincing?
1
—
—